Source link : https://www.newshealth.biz/health-news/semaglutide-reduces-cv-events-and-diabetes-risk/
ORLANDO, Fla. — The glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide (Wegovy, Ozempic) reduced cardiovascular events and reduced the risk of progression to diabetes by 73% in people with established cardiovascular disease and obesity compared with placebo, regardless of baseline A1c levels, according to two new analyses of the SELECT trial. In the first of […]
Author : News Health
Publish date : 2024-06-23 17:45:47
Copyright for syndicated content belongs to the linked Source.
in Health